Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Gilead in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Gilead' s performance against key rivals in the ethical
pharmaceutical sector
- See how the strong sales growth of Atripla will be tempered by the
cannibalization of Truvada' s revenues
- Learn how the acquisition of Myogen has provided Gilead with a major
growth driver and a pathway to therapeutic diversification
View Cart
